| (Nasdaq: YDES) Shares Breaking MOU News (Low Float Biotech On Radar Watch)
*Get Our Updates Faster—Tap Here To Receive SMS Alerts*
January 6th Greetings, Friend!
YD Bio Ltd (Nasdaq: YDES) has come out with some game-changing, breaking news this morning.
Take a look:
YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development
Taipei, Taiwan, Jan. 06, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company has entered into a Memorandum of Understanding (the “MOU”) to merge with EG BioMed, a biotechnology company specializing in DNA methylation–based cancer diagnostics and AI-driven biomarker analytics. The proposed merger represents a strategic step in building an integrated, data-driven oncology platform spanning early cancer detection, real-world clinical data generation, and AI-enabled drug discovery. The MOU is non-binding and there can be no assurance that the parties will enter into definitive agreements, obtain required approvals, or consummate the merger on the terms contemplated or on any particular timeline. Any integration benefits, including potential revenue growth, platform expansion, or cost synergies, remain subject to numerous assumptions and risks and may not be realized1. The transaction is anticipated to close in 2026, subject to customary closing conditions, regulatory approvals, and the finalization of definitive agreements.
...
“Prior to this announcement, EG BioMed’s cancer detection platform was approved for clinical adoption at three affiliated medical centers of Taipei Medical University. It is now being integrated into hospital workflows to assist clinicians in monitoring treatment response, disease progression, and recurrence,” said Dr. Ethan Shen, Chairman and CEO of the Company. The Company notes that early use at these centers may demonstrate clinical and economic value, which could support wider adoption across additional institutions. Broader uptake, if achieved, may contribute to diagnostics revenue growth and inform future therapeutic development.
...
Read the full article here.
This part is important. It's critical to take note that YDES is a low float profile.
Sitting a under 2Mn shares in its float, volatility potential could become seriously heightened following today's major news announcement.
Review my initial (Nasdaq: YDES) report below and consider this low float Biotech idea for your radar. -----
As 2026 begins, one biotechnology company is charging forward with remarkable momentum in a field where early detection and cellular precision continue to redefine the limits of possibility.
After reaching several major development milestones, the team is now shifting focus from validation to real-world clinical execution—advancing innovative eye treatments, next-generation diagnostics, and molecular research with the potential to transform how patients are cared for.
With its regulatory foundation laid and a catalyst-dense roadmap guiding the year ahead, the company appears ready to convert years of disciplined preparation into measurable medical breakthroughs.
Given the extremely low float—fewer than 2Mn shares—and an explosive news release this week, this little-known Nasdaq profile tops our watchlist:
*YD Bio Ltd (Nasdaq: YDES)*
YD Bio Limited is a biotechnology company focused on advancing clinical trials, new drug development, cancer prevention diagnostics, and limbal stem cell and exosome therapies with the potential to transform the treatment of diseases with high unmet medical need.
YD Bio Ltd. (Nasdaq: YDES) - Full Company Details
YD Bio Ltd focuses on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies.
Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.
Exosome therapy uses cell-derived vesicles to deliver proteins, RNA, and other molecules, promoting tissue repair, reducing inflammation, and supporting regenerative treatments for conditions like injuries, degenerative diseases, and immune disorders.
DNA Methylation Detection
Earlier detection. Improved outcomes.
Through proprietary DNA methylation analysis, the Company is developing non-invasive blood tests that help clinicians detect cancer earlier, monitor treatment response, and track recurrence risk. These tools are designed to give physicians actionable insights at every stage of care, supporting more effective, personalized treatment for patients.
Exosome-Based Ophthalmology Therapeutics
Regenerative science for eye health.
Exosomes are natural messengers that can help repair and restore cellular function. At YD Bio, the company is advancing exosome-based therapies to address large unmet needs in ophthalmology, including chronic conditions such as dry eye. By leveraging regenerative science, their goal is to deliver long-term solutions that improve patient comfort, vision, and quality of life.
YD Bio's Central Areas Of Focus
Innovating across multiple platforms in heal-thcare. | 
